ABD-3001 is under clinical development by Advanced BioDesign and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ABD-3001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ABD-3001 overview

ABD-3001 (sefaldin) is under development for the treatment of acute myelocytic leukemia, non-small cell lung cancer, breast cancer, melanoma, osteosarcoma, pancreatic cancer, myelodysplastic syndrome and colorectal cancer. It acts by targeting aldehyde dehydrogenase family 1 member A3 (ALDH1A3) and retinal dehydrogenase 1 (ALDH1A1). It is administered through intravenous route.

Advanced BioDesign overview

Advanced BioDesign (ABD) carries out the development of novel anticancer drugs. The company offers a therapeutic approach for acute myeloid leukemia and other cancers with high unmet medical needs. It provides ABD-3001 which is a small-molecule inhibitor of the ALDH family. ABD-3001 is used for the treatment of a wide range of cancers, including acute myeloid leukemia, non-small cell lung cancer, breast cancer, melanoma, and osteosarcoma. ABD is headquartered in Saint-Priest, France.

For a complete picture of ABD-3001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.